How Do Prescription Drug Tiers Work? The 2026 Connecticut Guide to Formularies, Copays, and Specialty Drug Coverage

Why Drug Tiers Matter More Than You Think

If you take any prescription regularly — for cholesterol, blood pressure, diabetes, depression, asthma, autoimmune disease, GLP-1 weight loss, ADHD, MS, oncology, or HIV — the tier that drug sits on inside your insurance plan’s formulary determines whether you pay $5 a month or $850 a month for the exact same medication. The difference is not what the drug costs the insurer; the difference is how the insurer has classified it. And drug-tier classification varies dramatically between carriers, between plans within a single carrier, and from year to year as formularies are reshuffled every January 1.

Connecticut shoppers routinely pick a health plan based on premium and deductible, never check the formulary, and discover in February that their long-time medication is now Tier 4 instead of Tier 2 on their new plan — turning a $35/month copay into a $245/month obligation. This article exists to prevent that surprise. We map every 2026 tier structure on every Connecticut commercial and Medicare carrier, explain prior authorization and step therapy in plain English, show you how the Inflation Reduction Act’s new $2,000 Part D cap actually works, and provide a checklist for verifying your prescriptions before you enroll.

A free 20-minute formulary review with a licensed Connecticut broker — Antonucci, Joseph (CT #21658409) at We Find Your Insurance — is the single most cost-effective use of an hour for anyone managing chronic medications. He runs every drug you take through every plan in your ZIP code and shows you the per-script and annual cost differences before you enroll.

What a Formulary Actually Is

A formulary is the list of prescription drugs your health insurance plan agrees to cover and the rules it applies to each one. Every commercial health plan and every Medicare Part D plan must publish its formulary on its website. The formulary specifies for every drug: the tier (which determines your cost-sharing), whether prior authorization is required, whether step therapy applies, whether quantity limits apply, what dosages are covered, what brand-name and generic alternatives are recognized, and whether the drug is available through a preferred pharmacy network.

Formularies are constructed by Pharmacy & Therapeutics (P&T) Committees inside each insurer or pharmacy benefit manager (PBM). The three dominant U.S. PBMs — CVS Caremark, Express Scripts, and OptumRx — each maintain their own master formularies that get customized for individual insurance plans. Anthem CT uses CarelonRx (an Elevance Health PBM); ConnectiCare uses Express Scripts; CTCare Benefits uses CVS Caremark. Each PBM updates its formularies quarterly, with the largest changes occurring on January 1 each year.

Sources: CT Insurance Department Drug Coverage Resources

Federal law (ACA Essential Health Benefits) requires every commercial plan sold in Connecticut to cover at least one drug from every USP therapeutic category, and Medicare Part D rules require coverage of essentially every drug in six ‘protected classes’ (antidepressants, antipsychotics, anticonvulsants, immunosuppressants, antiretrovirals, antineoplastics). But within these baseline requirements, insurers have wide latitude to tier drugs, demand prior authorization, and impose step therapy.

The Standard 5-Tier Structure (2026)

Almost every modern formulary uses a 5-tier (sometimes 6-tier) structure. The tiers are organized roughly by cost and clinical preference — Tier 1 is the cheapest for both insurer and patient; Tier 5 is the most expensive specialty drugs.

Standard 2026 Formulary Tier Structure

Note: not every plan uses six tiers. Many CT commercial plans collapse Tier 5 and Tier 6 into a single specialty tier. Medicare Part D 2026 plans almost universally use five tiers because CMS requires consistency for Annual Notice of Change disclosure. Bronze and Catastrophic plans tend to apply deductible to all drug tiers (you pay full negotiated price until you hit the deductible). Silver, Gold, and Platinum plans typically waive the deductible for Tier 1 and Tier 2, applying it only to Tiers 3–5.

Commercial (Access Health CT + Employer) Tier Costs for 2026

Here’s what real 2026 Access Health CT plans charge for prescriptions at each tier, based on standard Silver-tier benefit designs:

2026 Access Health CT Silver Plan Rx Costs (Typical)

Real-world example: a Hartford resident on Lipitor 20mg (generic atorvastatin, Tier 1) pays $5–$10/month on any CT Silver plan — no deductible required. The same resident on Eliquis (apixaban, Tier 3 preferred brand for atrial fibrillation) pays $60–$70/month AFTER meeting the $5,500 deductible. If they switch carriers and Eliquis is reclassified as Tier 4 on the new plan, that becomes $245/month at 30% coinsurance after deductible. Same drug, same dose — different tier, different cost.

ACA preventive drug requirement: every commercial CT plan must cover certain preventive medications at $0 with no deductible regardless of tier. These include statins for cardiovascular prevention, generic contraceptives, smoking cessation medications, low-dose aspirin for cardiovascular prevention in adults 50–59, folic acid for women planning pregnancy, immunizations, and HIV pre-exposure prophylaxis (PrEP, currently Truvada/Descovy generic equivalents). Insurers cannot apply tier copays or deductibles to these.

Sources: HealthCare.gov Preventive Drug List

Medicare Part D Tier Costs and the IRA $2,000 Cap

Medicare Part D underwent its most consumer-friendly transformation in history on January 1, 2025, with full effect through 2026. The Inflation Reduction Act capped annual out-of-pocket prescription costs at $2,000 per beneficiary, eliminated the catastrophic-tier coinsurance, and capped insulin at $35/month across all Part D plans. The pre-IRA system had no annual cap — beneficiaries on specialty drugs routinely paid $8,000–$12,000/year out of pocket. As of 2026, that exposure ends at $2,000.

2026 Medicare Part D Standard Benefit Structure

Practical effect: a Connecticut Medicare beneficiary on Eliquis at $9,300/year total cost (Tier 3 in most 2026 Part D plans) used to pay $1,800–$2,400/year out of pocket. In 2026, they pay copays/coinsurance until they reach $2,000 total — then $0 for the rest of the year. A beneficiary on Humira biosimilar at $87,000/year total cost used to pay $6,500/year out of pocket. In 2026, they pay $2,000 total. The savings are largest for the sickest beneficiaries.

Sources: CMS Part D 2026 Standard Benefit

Medicare Prescription Payment Plan (M3P): starting January 2025 and continuing in 2026, every Part D enrollee can opt to spread the $2,000 annual cap across monthly installments rather than paying spikes when expensive prescriptions are filled. This eliminates the January–February cash-flow problem that traditionally hit beneficiaries who hit the deductible immediately. Brokers help enroll Medicare beneficiaries in M3P at no cost.

Specialty Drugs (Tier 4 & 5) — Where the Money Is

Specialty drugs are the highest-cost prescription category and the area where formulary placement matters most. Specialty drugs are typically biologics (large-molecule injectable proteins), gene therapies, oral oncology medications, MS drugs, RA drugs, HIV antiretrovirals, hepatitis C cures, and certain autoimmune treatments. A single specialty drug can cost $4,000–$30,000 per month at wholesale; some gene therapies cost $400,000+ for a one-time treatment.

Common Specialty Drug Categories on Connecticut Formularies

• Autoimmune biologics: Humira (adalimumab — now with biosimilar competition), Enbrel, Stelara, Cosentyx, Skyrizi, Rinvoq, Dupixent
• MS drugs: Ocrevus, Kesimpta, Tysabri, Tecfidera, Aubagio
• Oncology orals: Ibrance, Verzenio, Imbruvica, Tagrisso, Enhertu
• GLP-1 weight loss / diabetes: Ozempic, Wegovy, Mounjaro, Zepbound
• Hepatitis C cures: Mavyret, Epclusa, Vosevi
• HIV: Biktarvy, Triumeq, Descovy (PrEP), Cabenuva (long-acting injectable)
• Cystic fibrosis: Trikafta
• PCSK9 inhibitors: Repatha, Praluent
• Migraine prevention CGRPs: Aimovig, Ajovy, Emgality, Vyepti, Nurtec, Qulipta
• Rare disease enzyme replacements: Cerezyme, Elaprase, Soliris

GLP-1 weight loss specific note: as of 2026, the major Connecticut commercial carriers cover Ozempic and Mounjaro for Type 2 diabetes with prior authorization but have inconsistent coverage of Wegovy and Zepbound for weight loss alone. Anthem CT typically requires BMI ≥35 or BMI ≥27 with comorbidities, plus 6 months of documented lifestyle intervention, plus a board-certified obesity medicine prescriber. ConnectiCare and CTCare Benefits have similar but plan-specific criteria. Medicare Part D does NOT cover weight-loss GLP-1s under any circumstance (federal law); it covers them only when prescribed for Type 2 diabetes.

Specialty drug cap mechanics: many CT commercial plans cap specialty drug coinsurance per script per month — for example, Anthem CT’s $1,000/month specialty cap means a Humira biosimilar at $5,400 wholesale costs the member $1,000/month maximum, not the 30% coinsurance that would otherwise be $1,620. This cap is the difference between affordable and ruinous for chronic specialty users. Confirm cap in your Summary of Benefits and Coverage before enrolling.

Prior Authorization — What It Is and How to Get Past It

Prior authorization (PA) is the insurer’s required approval before they’ll pay for certain drugs. It’s used to ensure the drug is being prescribed for an FDA-approved indication, that lower-cost alternatives have been tried, and to enforce quantity limits. Roughly 25–35% of all specialty drugs and 10–15% of brand-name Tier 3/4 drugs on Connecticut formularies require prior authorization. The PA process takes 1–14 days; emergency 24-hour expedited PAs are available for urgent clinical situations.

What’s Typically Required in a Prior Authorization Request

• Patient’s diagnosis (ICD-10 code) and clinical history
• FDA-approved indication match (or documented medical necessity for off-label)
• Documentation that step therapy/lower-cost alternatives have been tried (if applicable)
• Lab results, imaging, or specialist evaluation supporting the prescription
• Prescriber’s NPI and specialty (some PAs require board-certified specialist)
• Treatment duration and dose justification
• Failed therapies and adverse reactions to alternatives
• Sometimes patient sign-off on a chronic condition management plan

How to navigate prior authorization efficiently: get your prescriber’s office to use the carrier’s electronic prior authorization (ePA) portal (CoverMyMeds, Surescripts) — these resolve in hours, not days. Document everything: prior medications, allergies, prior side effects. If denied, request a peer-to-peer review (your doctor calls the insurer’s medical director). If still denied, file a written appeal — Connecticut law requires a response within 30 days for non-urgent appeals and 72 hours for urgent. The CT Insurance Department adjudicates external reviews when internal appeals fail; success rates on properly documented external reviews exceed 50%.

Sources: CT Insurance Department Appeals Process

Step Therapy — The ‘Fail First’ Rule

Step therapy (also called ‘fail-first’) requires that you try lower-cost alternatives BEFORE the insurer pays for a more expensive drug. The classic example: insurers require trial of a generic statin (atorvastatin, rosuvastatin) before approving Repatha (a $7,000/year PCSK9 inhibitor). Step therapy is common for autoimmune biologics (try methotrexate or a TNF inhibitor first before Stelara/Skyrizi), MS drugs (try oral DMTs before infusions), and migraine prevention CGRPs (try beta-blockers and topiramate first).

Connecticut step therapy protections: CT state law (CGS §38a-510a) requires insurers to grant step therapy exceptions when: the required drug is contraindicated; the required drug is expected to cause an adverse reaction; the patient has tried the required drug and failed; the patient is stable on the requested drug from previous coverage; or the required drug is not expected to be clinically effective. Exception requests must be granted within 72 hours for non-urgent and 24 hours for urgent. This is stronger than federal baseline.

Documenting a Step Therapy Exception

• Prior trial of required drugs (medication name, dose, duration, outcome)
• Documented adverse effects or treatment failure with required drugs
• Specialist letter explaining clinical rationale for requested drug
• Lab data, imaging, or symptom diaries supporting necessity
• If switching from prior coverage: documentation of stability on requested drug
• ICD-10 diagnoses justifying the more expensive medication

Quantity Limits and Day Supplies

Quantity limits cap how much of a drug can be filled per prescription. Common examples: triptans for migraine limited to 9 tablets per 30 days; opioids limited per state PMP rules; sleep aids limited to 30-day supply; GLP-1s limited to specific dose escalation schedules. Day supplies typically run 30 days at retail pharmacy and 90 days at mail-order or preferred 90-day retail (CVS, Walgreens, Big Y in CT). Specialty drugs are often limited to 30-day fills due to wholesale cost.

90-day fills are the single biggest cost-saving change most CT residents can make. Tier 1 and Tier 2 generics on 90-day mail-order typically cost 2x the retail 30-day copay — meaning 3 months for the price of 2. Annual savings can reach $100–$400 per drug. Talk to your prescriber about converting maintenance medications to 90-day fills at the first refill of the calendar year.

Generic vs Brand vs Biosimilar — The Real Differences

Generic drugs are FDA-approved bioequivalent versions of brand-name drugs that have lost patent protection. Generics must meet identical safety, strength, quality, dosage, and route of administration standards. They typically cost 70–95% less than the brand. Biosimilars are the biologic equivalent — FDA-approved ‘highly similar’ versions of branded biologics (Humira biosimilars like Hadlima, Amjevita, Cyltezo, etc.). Biosimilars typically cost 30–60% less than the reference biologic.

The 2026 biosimilar reality for Connecticut: Humira biosimilars have triggered the most aggressive formulary reshuffling in pharmaceutical history. Anthem CT, ConnectiCare, and CTCare Benefits have all moved Humira to non-preferred status and put one or two biosimilars on preferred specialty tier. Patients stable on branded Humira are being asked to switch to biosimilars. Insurers cite cost savings; clinicians cite generally equivalent outcomes; some patients report differences in injection device experience. Brokers help patients navigate the transition.

Common 2026 Connecticut Generic Substitutions

• Lipitor → atorvastatin (Tier 1)
• Crestor → rosuvastatin (Tier 1)
• Plavix → clopidogrel (Tier 1)
• Synthroid → levothyroxine (Tier 1)
• Lexapro → escitalopram (Tier 1)
• Cymbalta → duloxetine (Tier 2 generic)
• Advair → fluticasone/salmeterol (Tier 2 or AB-rated generic)
• Humira → adalimumab-aacf, adalimumab-bwwd, etc. (Tier 5 preferred specialty)
• Enbrel → currently no FDA-approved biosimilar substitution (still Tier 5 brand)
• Lantus → insulin glargine (Tier 2 — IRA $35 cap)

Mail Order, 90-Day Fills, and Pharmacy Networks

Most CT carriers contract with national mail-order pharmacies — CarelonRx Home Delivery (Anthem), Express Scripts Pharmacy (ConnectiCare), CVS Caremark Mail Service (CTCare Benefits) — to deliver 90-day maintenance medication fills to your door. The savings vs. retail 30-day fills usually equal one month’s free copay per quarter per drug. Specialty drugs almost always require a specialty pharmacy partner (Accredo, CVS Specialty, CarelonRx Specialty) rather than retail pickup; the specialty pharmacy handles cold-chain shipping, prior authorization documentation, and copay assistance enrollment.

Pharmacy Network Tiers (Typical 2026 CT)

• Preferred retail: large chains (CVS, Walgreens, Stop & Shop, Big Y, ShopRite, Costco) at lowest copay
• Standard retail: independent pharmacies, smaller chains at higher copay
• Out-of-network: very few CT plans cover out-of-network pharmacies — verify before assuming
• Mail-order: 90-day supply at 2x retail copay (one month free per quarter)
• Specialty pharmacy: required for Tier 5 drugs; insurer designates the pharmacy

Formulary Exclusions and How to Appeal

Formulary exclusions are drugs the insurer has decided NOT to cover at all. The list typically includes: drugs the insurer deems lifestyle (most weight-loss drugs unless diabetic indication), most cosmetic dermatology, most fertility drugs, most erectile dysfunction drugs in commercial plans, and brand-name drugs where the insurer has decided to cover only the generic. If your drug is excluded, you pay 100% retail price.

Appealing a formulary exclusion: you have a federal right under the ACA and state right under CT law to request a formulary exception when no covered drug is appropriate for your condition. Process: (1) your prescriber submits a clinical justification to the carrier; (2) carrier issues decision within 72 hours (24 hours urgent); (3) if denied, request internal appeal; (4) if denied again, request external review through CT Insurance Department. External review success rates on properly documented appeals exceed 40%. Brokers help patients organize documentation but cannot file appeals on the patient’s behalf — the prescriber leads.

Sources: CT Insurance Department External Review

What Connecticut Carriers Use in 2026

Each major Connecticut carrier uses a different PBM and a different master formulary. Here’s the 2026 landscape:

2026 Connecticut Carrier PBMs and Formulary Notes

Critical point: the same drug can sit on Tier 2 at one carrier and Tier 4 at another. A patient on Trulicity might pay $50/month at Anthem and $290/month at ConnectiCare for an identical prescription. Annual savings from picking the right carrier for your specific drug list can exceed $3,000–$5,000 for chronic specialty users. This is why drug-by-drug formulary review is the highest-ROI step in plan selection.

Six Real Connecticut Prescription Scenarios

Case 1 — 42-year-old in Stamford on Lexapro, atorvastatin, omeprazole (all Tier 1 generics). Total annual prescription cost on any Silver plan: $360. Tier choice essentially doesn’t matter for this household. Outcome: pick on premium and network, drugs are a non-factor.

Case 2 — 56-year-old Hartford resident with atrial fibrillation on Eliquis. On Anthem CT HMO Silver: Eliquis is Tier 3 preferred brand, $60/month copay after $5,500 deductible. On ConnectiCare PassageCT: Eliquis is also Tier 3 at $60/month. Switch to off-exchange Cigna for PPO: Eliquis Tier 3 at $55/month. Differences are minor here; drug is well-positioned across carriers. Outcome: choose based on network and premium, not drug.

Case 3 — 48-year-old in New Haven with rheumatoid arthritis on Humira (now switching to a biosimilar). Anthem CT EPO formulary: Hadlima (adalimumab-bwwd) Tier 5 preferred specialty at 30% coinsurance, capped at $1,000/month = $12,000/year. ConnectiCare formulary: Amjevita Tier 5 at 35% coinsurance, no cap = $22,800/year potential exposure on $65k wholesale. Outcome: Anthem saves $10,800/year for this patient. Verified before enrolling.

Case 4 — 67-year-old in Fairfield on Medicare Part D. Takes Eliquis, Jardiance, atorvastatin, and Eliquis 60-day supply. 2026 plan: WellCare Value Script Part D at $0/month premium. Annual drug cost: hits $2,000 cap by July. After cap: $0 for rest of year. 2025 same scenario would have been $4,600 out of pocket. IRA cap saves this beneficiary $2,600/year. Outcome: huge win from IRA reform.

Case 5 — 39-year-old solo entrepreneur in Norwich on Ozempic for Type 2 diabetes. On Anthem CT HMO Silver: Ozempic Tier 3 with prior authorization requiring A1C >7.0 documented, metformin trial documented = $80/month after deductible. Same patient asking for Wegovy for weight loss (no diabetes): denied as not covered; appealed; denied. Outcome: works with prescriber to maintain Ozempic for diabetes diagnosis. Avoids out-of-pocket $1,400/month for Wegovy cash pay.

Case 6 — 71-year-old in Greenwich on Medicare with breast cancer on Verzenio (oral oncology, Tier 5). 2026 Part D plan: Humana Premier Rx Plan. Verzenio wholesale $14,500/month. Member hits $2,000 IRA cap in February, pays $0 for remainder of year. Pre-IRA exposure: $11,800/year. 2026 exposure: $2,000. Outcome: $9,800/year savings from IRA cap. Enrolled in Medicare Prescription Payment Plan to spread the $2,000 across 12 monthly installments (~$167/month).

How Drug Costs Interact With Your MOOP

On commercial plans, prescription cost-sharing counts toward your federal out-of-pocket maximum. So a $1,000/month specialty drug copay will push you to your MOOP within 7–9 months. After hitting MOOP, all in-network covered drugs cost $0 for the rest of the year. This is the same dynamic as medical care — drug spending and medical spending both contribute to the same federal MOOP cap.

On Medicare Part D, prescription costs do NOT count toward Medicare Advantage MOOP or Medigap deductibles. Part D has its own separate annual cap — the IRA’s new $2,000 cap. If you have Medicare Advantage with Part D included, you have two separate caps: the in-network medical MOOP (up to $9,350 in 2026) and the Part D drug cap ($2,000). The interaction is favorable: high drug users hit $2,000 quickly and then drugs become free, while medical exposure continues until medical MOOP is met.

Sources: Out-of-pocket maximum guide (CT 2026)

Manufacturer Assistance and Copay Cards

Drug manufacturers operate three major financial assistance programs that can dramatically reduce out-of-pocket cost for branded medications:

• Copay cards (commercial insurance only) — bring branded drug copay down to $0–$25/month. Examples: Humira Complete Savings Card, Eliquis 360 Support, Ozempic Savings Card. NOT usable with Medicare or Medicaid by federal law.
• Patient Assistance Programs (PAPs) — free drug supply for uninsured or underinsured patients meeting income thresholds. Common across Lilly, Pfizer, Bristol-Myers Squibb, Novo Nordisk, Sanofi.
• Foundation-based copay assistance (Medicare & commercial) — independent foundations (PAN, HealthWell, Good Days, ALSO Foundation) provide copay grants for specific disease states. Critical for Medicare beneficiaries who can’t use copay cards.
• State pharmacy assistance: Connecticut’s ConnPACE for Medicare beneficiaries with income up to specific thresholds; supplements Medicare Part D drug costs.

Critical 2026 rule: insurers’ ‘copay accumulator’ programs (which used to refuse to count manufacturer copay card spending toward your deductible/MOOP) have been substantially restricted by federal court rulings and CT state law. As of 2026, Connecticut commercial plans MUST count copay card payments toward your deductible and MOOP when no medically appropriate generic alternative exists. This is stronger consumer protection than most states.

Drug-Tier Shopping Checklist Before Enrolling

• List EVERY prescription you currently take (drug name, strength, frequency, prescriber)
• Note any anticipated new prescriptions (planned surgery, chronic disease diagnosis, GLP-1 starting)
• Look up each drug on every plan’s formulary (online drug search tool or call broker)
• Note the tier and any restrictions (PA, step therapy, quantity limit) for each drug
• Calculate annual cost: per-fill copay × number of fills (most chronic drugs = 12 fills/year)
• Verify your pharmacy is in the carrier’s preferred network
• Check if specialty drugs require a specific specialty pharmacy
• Confirm whether the carrier covers your drug at 90-day mail-order
• Verify if any drug is on the ACA $0 preventive list (statins, contraceptives, etc.)
• For Medicare: confirm the drug is on the Part D formulary tier you expect
• If you anticipate hitting the Part D $2,000 cap, enroll in the Medicare Prescription Payment Plan

Drug Coverage Mistakes Connecticut Patients Make

• Picking a plan on premium alone without checking the formulary for chronic medications
• Assuming the same drug stays on the same tier when switching carriers — formularies vary wildly
• Not requesting a 90-day mail-order fill — leaving $100–$400/year on the table per chronic drug
• Letting a prior authorization lapse during a January 1 plan switch — pre-submit PAs in late December
• Not knowing about Connecticut’s step therapy exception law — failing to challenge fail-first requirements
• Failing to enroll in manufacturer copay cards on branded drugs — paying $200/month when $10/month is available
• Medicare beneficiaries assuming their old Part D plan stays best each year — re-shop annually during AEP
• Not enrolling in the Medicare Prescription Payment Plan when expecting $2,000+ in annual drug costs
• Assuming weight-loss GLP-1s are covered — most CT commercial plans require BMI + comorbidity documentation; Medicare doesn’t cover at all
• Filling specialty drugs at retail pharmacies — insurers redirect to a specialty pharmacy and may not pay retail
• Switching between branded and biosimilar without prescriber coordination — minor differences in injection devices and inactive ingredients can matter

How We Find Your Insurance Helps Connecticut Patients With Drug Coverage

We Find Your Insurance is a Farmington-based independent brokerage serving Connecticut residents at no cost. Brokers are paid identical commissions across plans, so the recommendation is independent. Licensed agent Antonucci, Joseph (CT #21658409) runs every household’s drug list against every available formulary before recommending a plan.

What a free 20-minute drug-tier review covers: complete inventory of current prescriptions; formulary tier check across every Connecticut commercial and Medicare Part D carrier; calculation of annual drug cost by plan; identification of manufacturer copay cards and foundation grants; coordination with your prescriber’s office on prior authorization requirements; enrollment in Medicare Prescription Payment Plan if applicable; and annual re-shop during Open Enrollment to capture formulary changes. No fee to the consumer.

Sources: Medicare Part D guide (CT 2026), Health insurance broker near me (CT 2026)

Frequently Asked Questions

What are drug tiers? Drug tiers are the levels insurance companies use to classify prescription drugs based on cost and clinical preference. Tier 1 generics are cheapest; Tier 5 specialty drugs are most expensive.

How many tiers are on a typical 2026 Connecticut formulary? Five tiers, sometimes six. Tier 1 generics, Tier 2 non-preferred generics, Tier 3 preferred brand, Tier 4 non-preferred brand, Tier 5 specialty (sometimes Tier 6 ‘select specialty’).

Does my prescription cost count toward my out-of-pocket maximum? On commercial plans, yes — every dollar you pay for in-network covered prescriptions counts toward the federal MOOP. On Medicare Part D, drug costs are capped separately at $2,000/year under the Inflation Reduction Act.

What is prior authorization? Prior authorization (PA) is the insurer’s required approval before paying for certain drugs. Roughly 25–35% of specialty drugs and 10–15% of brand-name Tier 3/4 drugs require PA in Connecticut.

What is step therapy? Step therapy requires you try lower-cost alternative drugs before the insurer pays for a more expensive one. Connecticut state law (CGS §38a-510a) allows exceptions when the required drug is contraindicated, has caused adverse reactions, has failed, or when you’re stable on the requested drug.

What’s the difference between a generic and a brand-name drug? Generics are FDA-approved bioequivalent versions of brand drugs that have lost patent protection. They cost 70–95% less and meet identical safety, strength, quality standards.

What’s a biosimilar? A biosimilar is the FDA-approved ‘highly similar’ version of a branded biologic drug (e.g., Humira biosimilars Hadlima, Amjevita, Cyltezo). Biosimilars cost 30–60% less than the reference biologic.

What’s the 2026 Medicare Part D annual out-of-pocket cap? $2,000. The Inflation Reduction Act capped annual prescription costs at $2,000 for every Medicare Part D beneficiary, with no further coinsurance after the cap is reached.

Does Medicare cover weight-loss GLP-1 drugs? No. Federal Medicare law prohibits Part D coverage of weight-loss drugs. Ozempic and Mounjaro are covered when prescribed for Type 2 diabetes; Wegovy and Zepbound are not covered for weight loss alone under Medicare.

Can I use a manufacturer copay card if I have Medicare? No. Federal law prohibits manufacturer copay cards from being used by Medicare and Medicaid beneficiaries. Medicare patients can use foundation-based copay assistance programs (PAN, HealthWell, Good Days) instead.

What happens to my prior authorization if I switch plans on January 1? It does not transfer. Every PA must be re-issued on the new plan. Stockpile a 90-day refill on the old plan before switching and have your prescriber pre-submit PAs to the new carrier in December.

Does Connecticut have state-level drug coverage protections? Yes. CT has stronger-than-federal step therapy exception law, a copay accumulator restriction requiring insurers to count copay card payments toward MOOP, and a robust external review process through the CT Insurance Department.

What’s the Medicare Prescription Payment Plan (M3P)? An IRS- and CMS-administered option allowing Part D beneficiaries to spread their $2,000 annual drug cap across 12 monthly installments instead of paying spikes at the pharmacy. Free to enroll; opt in through your Part D plan.

How often do formularies change? Annually on January 1 (largest changes), with mid-year additions and tier reassignments allowed under CMS and ACA rules. Insurers must provide 60 days’ notice for negative formulary changes affecting existing patients.

How do I find a Connecticut broker to run a formulary check? Call We Find Your Insurance at (860) 856-5894. Antonucci, Joseph (CT #21658409) runs every drug you take across every carrier’s formulary at no cost to you.

Frequently Asked Questions